Abstract 164P
Background
Immune checkpoint inhibitors (ICI) were demonstrated to extend survival in patients with metastatic esophageal squamous cell carcinoma (ESCC). However, the role of ICI in locally advanced ESCC is not yet established. Herein, we conducted a retrospective study to evaluate the efficacy and safety of ICI plus neoadjuvant concurrent chemoradiotherapy (CCRT) for patients with locally advanced ESCC.
Methods
ESCC patients treated with neoadjuvant CCRT were retrospectively recruited into our study. Patients were classified into ICI-CCRT and CCRT according to regimens during CCRT. ICI-CCRT referred to ICI plus chemoradiotherapy while CCRT referred to chemoradiotherapy alone. Kaplan-Meier curves were estimated for recurrent-free survival (RFS) and overall survival (OS).
Results
A total of 150 patients were enrolled into our study, with 43 patients in ICI-CCRT and 107 patients in CCRT group. The median age was 58.5 years old of our patients and median follow-up period were 22 months. As for patients in ICI-CCRT, 33 patients received nivolumab plus CCRT and 10 patients received pembrolizumab plus CCRT. The median RFS was not reach (NR) versus 16.2 months in ICI-CCRT and CCRT group, respectively (p= 0.016). The median OS was not reach (NR) versus 20.0 months in ICI-CCRT and CCRT group, respectively (p= 0.002). The response rates were significantly higher in IC-CCRT, accounting for 74 % versus 65 % in ICI-CCRT arm and CCRT arm, respectively. Multivariate analysis showed ICI-CCRT was an independent predictor associated with survival. Grade 3/4 adverse events were comparable between each group.
Conclusions
Neoadjuvant ICI-CCRT is superior to CCRT for locally advanced ESCC patients with similar toxicity profiles. Further prospective studies are warranted to validate our conclusions.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
519P - Final results and subgroup analysis of ORIENTAL: A phase IIIB study of durvalumab plus platinum-etoposide in first-line treatment of Chinese patients with extensive-stage small-cell lung cancer (ES-SCLC)
Presenter: Ying Cheng
Session: Poster Display
Resources:
Abstract
520P - Role of atezolizumab in controlling CNS progression in ES-SCLC
Presenter: Yoon Namgung
Session: Poster Display
Resources:
Abstract
521P - Camrelizumab combined with chemotherapy and apatinib as first-line therapy for extensive-stage small cell lung cancer: A phase II, single-arm, exploratory research
Presenter: Yanbin Zhao
Session: Poster Display
Resources:
Abstract
522P - Durvalumab plus etoposide and carboplatin for extensive-stage small cell lung cancer with mild idiopathic interstitial pneumonia
Presenter: Ichiro Nakachi
Session: Poster Display
Resources:
Abstract
523P - Camrelizumab plus apatinib as maintenance treatment in patients with extensive-stage small cell lung cancer who were responding or stable after standard first-line chemotherapy (CAMERA): Results from a single-arm, phase II trial
Presenter: Qi Wang
Session: Poster Display
Resources:
Abstract
524P - Treatment pattern and overall survival by lines of therapy among patients with advanced small cell lung cancer in Taiwan
Presenter: Kelly Huang
Session: Poster Display
Resources:
Abstract
525P - Development of diagnostic prediction score for malignant pleural effusion in lung cancer: MPE-Lung score
Presenter: Chaichana Chantharakhit
Session: Poster Display
Resources:
Abstract
526P - Burden and trends of tracheal, bronchus, and lung (TBL) cancer in Southeast Asia, East Asia, and Oceania from 1990-2019, and its projection of deaths to 2040: A benchmarking analysis
Presenter: Monika Chhayani
Session: Poster Display
Resources:
Abstract
527P - Efficacy of intraventricular chemotherapy with pemetrexed for leptomeningeal metastasis from lung adenocarcinoma: A retrospective study
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract
528P - Socioeconomic determinants of access to standard-of-care treatments in advanced and metastatic NSCLC in Hong Kong: A territory-wide study
Presenter: Ka Man Cheung
Session: Poster Display
Resources:
Abstract